Experimental Design Principles
Q: True or False: In a double-blind clinical trial, neither the participants nor the researchers administering the treatment know who is receiving the active drug versus the placebo.
Did You Know?
The key disadvantage of using polyclonal antibodies in quantitative IHC assays is their inherent batch-to-batch variability, which compromises reproducibility and standardization. Polyclonal antibodies are produced by immunizing an animal (e.g., a rabbit) with an antigen and harvesting the serum, which contains a heterogeneous mixture of antibodies from many different B-cell clones. Each animal, and even each bleed from the same animal, can produce a slightly different mixture of antibodies with varying affinities and specificities for different epitopes on the antigen. This means that a new batch of polyclonal antiserum may have a different staining profile (intensity, background, even specificity) compared to the previous batch. For quantitative assays where the intensity of staining is measured and compared (e.g., scoring HER2 or hormone receptors), this variability can introduce significant error and make it difficult to establish stable, long-term scoring thresholds. Monoclonal antibodies, being derived from a single clone, offer much greater batch consistency and are therefore preferred for quantitative diagnostic applications.
Social Sharing!
Share your knowledge:
Zambia